The other actionable alterations (in ROS1, ERBB2, MET, and BRAF) were found in NSCLC outpatients or inpatients with a poor PS, not eligible for enrollment in a clinical trial or active treatment. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.